LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 38

Search options

  1. Article ; Online: From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6.

    Melms, Johannes C / Ho, Patricia / Rogava, Meri / Izar, Benjamin

    Genes and immunity

    2023  Volume 25, Issue 1, Page(s) 82–84

    Abstract: Immune evasion is a hallmark of cancer, yet the underlying mechanisms are often unknown in many patients. Using single-cell transcriptomics analysis, we previously identified the co-stimulator CD58 as part of a cancer cell-intrinsic immune checkpoint ... ...

    Abstract Immune evasion is a hallmark of cancer, yet the underlying mechanisms are often unknown in many patients. Using single-cell transcriptomics analysis, we previously identified the co-stimulator CD58 as part of a cancer cell-intrinsic immune checkpoint resistance signature in patient melanoma tissue. We subsequently validated CD58 loss as a driver of immune evasion using a patient-derived co-culture model of cancer and cytotoxic tumor-infiltrating lymphocytes in a pooled single-cell perturbation experiment, where we additionally observed concurrent upregulation of PD-L1 protein expression in melanoma cells with CD58 loss. In our most recent study, we uncovered the mechanisms of immune evasion mediated by CD58 loss, including impaired T cell activation and infiltration within tumors, as well as inhibitory signaling by PD-L1 via a shared regulator, CMTM6. Thus, cancer cell-intrinsic reduction of CD58 represents a multi-faceted determinant of immune evasion. Furthermore, its reciprocal interaction with PD-L1 via CMTM6 provides critical insights into how co-inhibitory and co-stimulatory immune cues are regulated.
    MeSH term(s) Humans ; B7-H1 Antigen/genetics ; Melanoma/genetics ; Immune Evasion ; Cell Line, Tumor ; Signal Transduction
    Chemical Substances B7-H1 Antigen
    Language English
    Publishing date 2023-12-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2060566-3
    ISSN 1476-5470 ; 1466-4879
    ISSN (online) 1476-5470
    ISSN 1466-4879
    DOI 10.1038/s41435-023-00224-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.

    Thummalapalli, Rohit / Melms, Johannes C / Mier, James / Izar, Benjamin

    Melanoma research

    2020  Volume 30, Issue 2, Page(s) 219–222

    Abstract: The use of either immune checkpoint blockade or RAF/MEK inhibitors represents standard of care treatment options for metastatic melanoma. Each class of these drugs has distinct response kinetics, adverse effects, and unique clinical challenges. ... ...

    Abstract The use of either immune checkpoint blockade or RAF/MEK inhibitors represents standard of care treatment options for metastatic melanoma. Each class of these drugs has distinct response kinetics, adverse effects, and unique clinical challenges. Combination of immune checkpoint blockade and RAF/MEK inhibitors may result in rapid and durable responses, however, the potential adverse effects of such combinations are poorly characterized. Here, we describe the case of a patient with BRAF-mutant melanoma who received an initial infusion of anti-PD-1 therapy while taking RAF/MEK inhibitors and experienced severe acute kidney injury, an otherwise infrequent side effect of any of these drugs alone. Treatment with corticosteroids rapidly reversed this process, indicating an underlying immune-mediated complication. A deeper understanding of potential adverse effects of combination therapies and their potential mechanisms should be carefully considered in the treatment landscape for melanoma and other cancers.
    MeSH term(s) Acute Kidney Injury/chemically induced ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Melanoma/complications ; Melanoma/drug therapy ; Melanoma/pathology ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Skin Neoplasms/complications ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology
    Chemical Substances Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2020-02-12
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1095779-0
    ISSN 1473-5636 ; 0960-8931
    ISSN (online) 1473-5636
    ISSN 0960-8931
    DOI 10.1097/CMR.0000000000000646
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

    Altorki, Nasser K / Walsh, Zachary H / Melms, Johannes C / Port, Jeffery L / Lee, Benjamin E / Nasar, Abu / Spinelli, Cathy / Caprio, Lindsay / Rogava, Meri / Ho, Patricia / Christos, Paul J / Saxena, Ashish / Elemento, Olivier / Bhinder, Bhavneet / Ager, Casey / Amin, Amit Dipak / Sanfilippo, Nicholas J / Mittal, Vivek / Borczuk, Alain C /
    Formenti, Silvia C / Izar, Benjamin / McGraw, Timothy E

    Nature communications

    2024  Volume 15, Issue 1, Page(s) 225

    Language English
    Publishing date 2024-01-03
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-023-44575-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.

    Ager, Casey R / Zhang, Mingxuan / Chaimowitz, Matthew / Bansal, Shruti / Obradovic, Aleksandar / Rogava, Meri / Melms, Johannes C / McCann, Patrick / Spina, Catherine / Drake, Charles G / Dallos, Matthew C / Izar, Benjamin

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow ... ...

    Abstract Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow cytometry panel and performed high-throughput analyses in critical contexts. We leveraged two distinct preclinical models that recapitulate cancer immunoediting (NPK-C1) and immune checkpoint blockade (ICB) response (MC38), respectively, and profiled multiple relevant tissues at and around key inflection points of immune surveillance and escape and/or ICB response. Machine learning-driven data analysis revealed a pattern of KLRG1 expression that uniquely identified intratumoral effector CD4 T cell populations that constitutively associate with tumor burden across tumor models, and are lost in tumors undergoing regression in response to ICB. Similarly, a Helios
    Language English
    Publishing date 2023-01-02
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.01.01.522340
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.

    Ager, Casey R / Zhang, Mingxuan / Chaimowitz, Matthew / Bansal, Shruti / Tagore, Somnath / Obradovic, Aleksandar / Jugler, Collin / Rogava, Meri / Melms, Johannes C / McCann, Patrick / Spina, Catherine / Drake, Charles G / Dallos, Matthew C / Izar, Benjamin

    Journal for immunotherapy of cancer

    2023  Volume 11, Issue 9

    Abstract: Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow ... ...

    Abstract Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow cytometry panel and performed high-throughput analyses in critical contexts. We leveraged two distinct preclinical models that recapitulate cancer immunoediting (NPK-C1) and immune checkpoint blockade (ICB) response (MC38), respectively, and profiled multiple relevant tissues at and around key inflection points of immune surveillance and escape and/or ICB response. Machine learning-driven data analysis revealed a pattern of KLRG1 expression that uniquely identified intratumoral effector CD4 T cell populations that constitutively associate with tumor burden across tumor models, and are lost in tumors undergoing regression in response to ICB. Similarly, a Helios
    MeSH term(s) Humans ; CD4-Positive T-Lymphocytes ; T-Lymphocyte Subsets ; Carcinoma, Renal Cell ; Kidney Neoplasms ; Immunotherapy ; Biomarkers ; Receptors, Immunologic ; Lectins, C-Type
    Chemical Substances Biomarkers ; KLRG1 protein, human ; Receptors, Immunologic ; Lectins, C-Type
    Language English
    Publishing date 2023-08-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-006782
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells.

    Walsh, Zachary H / Shah, Parin / Kothapalli, Neeharika / Nikolenyi, Gergo / Shah, Shivem B / Leuzzi, Giuseppe / Mu, Michael / Ho, Patricia / Abuzaid, Sinan / Brodtman, Zack D / Vasan, Neil / AlQuraishi, Mohammed / Milner, Joshua D / Ciccia, Alberto / Melms, Johannes C / Izar, Benjamin

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Base editing enables generation of single nucleotide variants, but large-scale screening in primary human T cells is limited due to low editing efficiency, among other ... ...

    Abstract Base editing enables generation of single nucleotide variants, but large-scale screening in primary human T cells is limited due to low editing efficiency, among other challenges
    Language English
    Publishing date 2023-12-14
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.12.13.571465
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Author Correction

    Nasser K. Altorki / Zachary H. Walsh / Johannes C. Melms / Jeffery L. Port / Benjamin E. Lee / Abu Nasar / Cathy Spinelli / Lindsay Caprio / Meri Rogava / Patricia Ho / Paul J. Christos / Ashish Saxena / Olivier Elemento / Bhavneet Bhinder / Casey Ager / Amit Dipak Amin / Nicholas J. Sanfilippo / Vivek Mittal / Alain C. Borczuk /
    Silvia C. Formenti / Benjamin Izar / Timothy E. McGraw

    Nature Communications, Vol 15, Iss 1, Pp 1-

    Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

    2024  Volume 1

    Keywords Science ; Q
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: Mapping human natural killer cell development in pediatric tonsil by imaging mass cytometry and high-resolution microscopy.

    Hegewisch-Solloa, Everardo / Melsen, Janine E / Ravichandran, Hiranmayi / Rendeiro, André F / Freud, Aharon G / Mundy-Bosse, Bethany / Melms, Johannes C / Eisman, Shira E / Izar, Benjamin / Grunstein, Eli / Connors, Thomas J / Elemento, Olivier / Horowitz, Amir / Mace, Emily M

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Natural killer (NK) cells develop from CD34+ progenitors in a stage-specific manner defined by changes in cell surface receptor expression and function. Secondary lymphoid tissues, including tonsil, are sites of human NK cell development. Here we present ...

    Abstract Natural killer (NK) cells develop from CD34+ progenitors in a stage-specific manner defined by changes in cell surface receptor expression and function. Secondary lymphoid tissues, including tonsil, are sites of human NK cell development. Here we present new insights into human NK cell development in pediatric tonsil using cyclic immunofluorescence and imaging mass cytometry. We show that NK cell subset localization and interactions are dependent on NK cell developmental stage and tissue residency. NK cell progenitors are found in the interfollicular domain in proximity to cytokine-expressing stromal cells that promote proliferation and maturation. Mature NK cells are primarily found in the T-cell rich parafollicular domain engaging in cell-cell interactions that differ depending on their stage and tissue residency. The presence of local inflammation results in changes in NK cell interactions, abundance, and localization. This study provides the first comprehensive atlas of human NK cell development in secondary lymphoid tissue.
    Language English
    Publishing date 2023-09-06
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.09.05.556371
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens.

    Wang, Yiping / Fan, Joy Linyue / Melms, Johannes C / Amin, Amit Dipak / Georgis, Yohanna / Barrera, Irving / Ho, Patricia / Tagore, Somnath / Abril-Rodríguez, Gabriel / He, Siyu / Jin, Yinuo / Biermann, Jana / Hofree, Matan / Caprio, Lindsay / Berhe, Simon / Khan, Shaheer A / Henick, Brian S / Ribas, Antoni / Macosko, Evan Z /
    Chen, Fei / Taylor, Alison M / Schwartz, Gary K / Carvajal, Richard D / Azizi, Elham / Izar, Benjamin

    Nature genetics

    2023  Volume 55, Issue 1, Page(s) 19–25

    Abstract: Single-cell genomics enables dissection of tumor heterogeneity and molecular underpinnings of drug response at an unprecedented ... ...

    Abstract Single-cell genomics enables dissection of tumor heterogeneity and molecular underpinnings of drug response at an unprecedented resolution
    MeSH term(s) Humans ; Genomics/methods ; Gene Expression Profiling/methods ; Neoplasms/genetics ; Sequence Analysis, RNA/methods ; Whole Genome Sequencing
    Language English
    Publishing date 2023-01-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1108734-1
    ISSN 1546-1718 ; 1061-4036
    ISSN (online) 1546-1718
    ISSN 1061-4036
    DOI 10.1038/s41588-022-01268-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

    Altorki, Nasser K / Walsh, Zachary H / Melms, Johannes C / Port, Jeffery L / Lee, Benjamin E / Nasar, Abu / Spinelli, Cathy / Caprio, Lindsay / Rogava, Meri / Ho, Patricia / Christos, Paul J / Saxena, Ashish / Elemento, Olivier / Bhinder, Bhavneet / Ager, Casey / Amin, Amit Dipak / Sanfilippo, Nicholas J / Mittal, Vivek / Borczuk, Alain C /
    Formenti, Silvia C / Izar, Benjamin / McGraw, Timothy E

    Nature communications

    2023  Volume 14, Issue 1, Page(s) 8435

    Abstract: We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined ... ...

    Abstract We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation (DRT). The trial met its primary endpoint of major pathological response, which was significantly higher following DRT with no new safety signals. Here, we report on the prespecified secondary endpoint of disease-free survival (DFS) regardless of treatment assignment and the prespecified exploratory analysis of DFS in each arm of the trial. DFS at 2 and 3 years across patients in both arms of the trial were 73% (95% CI: 62.1-84.5) and 65% (95% CI: 52.5-76.9) respectively. For the exploratory endpoint of DFS in each arm of the trial, three-year DFS was 63% (95% CI: 46.0-80.4) in the durvalumab monotherapy arm compared to 67% (95% CI: 49.6-83.4) in the dual therapy arm. In addition, we report post hoc exploratory analysis of progression-free survival as well as molecular correlates of response and recurrence through high-plex immunophenotyping of sequentially collected peripheral blood and gene expression profiles from resected tumors in both treatment arms. Together, our results contribute to the evolving landscape of neoadjuvant treatment regimens for NSCLC and identify easily measurable potential biomarkers of response and recurrence.
    MeSH term(s) Humans ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Neoadjuvant Therapy ; Small Cell Lung Carcinoma/drug therapy ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase II as Topic
    Chemical Substances Antibodies, Monoclonal ; durvalumab (28X28X9OKV)
    Language English
    Publishing date 2023-12-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-023-44195-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top